Cite
HARVARD Citation
Wei, J. et al. (n.d.). P-130A phase I/II Trial of CRISPR-Cas9-mediated PD-1 knockout Epstein-Barr virus cytotoxic lymphocytes (EBV-CTLs) for advanced stage EBV associated malignancies - Trial in progress. Annals of oncology. p. . [Online].